True Wealth Design’s Verrica Pharmaceuticals VRCA Stock Holding History

True Wealth Design’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1	Closed	-$4	–	2837
2025 Q1	$4	Buy	+1	New	+$6	﹤0.01%	2646

Other funds holding VRCA

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sovran Advisors San Diego, California $1.27B AUM 18.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

True Wealth Design's VRCA Position: Q2 2025 in Review

True Wealth Design sold out of Verrica Pharmaceuticals (VRCA) in Q2 2025, closing a stake of 1 share — an estimated $4 sold.

True Wealth Design first reported a position in VRCA in Q1 2025 and held it in 1 quarter. The position peaked at $4 in Q1 2025. 58 funds tracked by Wall St. Rank hold VRCA as of Q2 2025.

True Wealth Design reported no remaining Verrica Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
True Wealth Design sold 1 Verrica Pharmaceuticals share in Q2 2025, an estimated $4.
True Wealth Design first reported a position in Verrica Pharmaceuticals in Q1 2025 and held it in 1 quarter.
True Wealth Design's Verrica Pharmaceuticals position peaked at $4 in Q1 2025.
58 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2025.

Based on True Wealth Design's 13F filing for Q2 2025, filed 6 Aug 2025.